Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPLENTY-pvtt: Neoadjuvant IMRT + PD-1 Blockade + Lenvatinib for HCC with PVTT
NCT05339581Unknown
- Sponsor
- Renji Hospital
- Start
- May 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Renji Hospital. Primary endpoint: PVTT Response Rate/Necrosis Rate at 12 months. Status: unknown.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05339581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339581.